Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

The Protein Sequencing Companytm, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, ...

Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and othersAkribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell ...

Registration: The Indian Institute of Science Education and Research (IISER) has released the information brochure for the ...

As the CBSE Class 10 Science Board exam approaches on February 20, 2025, students are refining their preparation strategies.

Eligible candidates can apply for the Graduate Aptitude Test- Biotechnology (GAT-B) 2025 at exams.nta.ac.in up to March 3.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Adding US stocks to your investment portfolio can offer growth potential, stability, and diversification. Indian investors ...

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced ...

Fresh from its landmark US regulatory approval for its stem-cell product for paediatric graft-versus-host disease (GvHD), ...